eFFECTOR Therapeutics, Inc.
EFTR · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $162 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $28 | $30 | $26 | $27 |
| Gross Profit | -$28 | $132 | -$26 | -$27 |
| % Margin | – | 81.5% | – | – |
| R&D Expenses | $5,306 | $6,043 | $5,355 | $4,881 |
| G&A Expenses | $3,090 | $2,524 | $2,500 | $2,974 |
| SG&A Expenses | $3,090 | $2,524 | $2,500 | $2,974 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$14 |
| Operating Expenses | $8,396 | $8,567 | $7,855 | $7,855 |
| Operating Income | -$8,396 | -$8,597 | -$8,303 | -$7,855 |
| % Margin | – | -5,306.8% | – | – |
| Other Income/Exp. Net | -$438 | -$532 | -$448 | -$509 |
| Pre-Tax Income | -$8,834 | -$9,129 | -$8,303 | -$8,364 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,834 | -$9,129 | -$8,303 | -$8,364 |
| % Margin | – | -5,635.2% | – | – |
| EPS | -3.31 | -3.42 | -3.36 | -4.37 |
| % Growth | 3.2% | -1.8% | 23.1% | – |
| EPS Diluted | -3.31 | -3.42 | -3.36 | -4.37 |
| Weighted Avg Shares Out | 2,670 | 2,670 | 2,471 | 1,913 |
| Weighted Avg Shares Out Dil | 2,670 | 2,670 | 2,471 | 1,913 |
| Supplemental Information | – | – | – | – |
| Interest Income | $323 | $223 | $296 | $227 |
| Interest Expense | $749 | $758 | $750 | $722 |
| Depreciation & Amortization | $28 | $30 | $26 | $27 |
| EBITDA | -$8,057 | -$8,342 | -$7,829 | -$7,615 |
| % Margin | – | -5,149.4% | – | – |